Navigation Links
PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
Date:12/4/2009

s, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, unexpected financial obligations that could increase the rate of our cash consumption, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, significant additional research work, non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for the Company's lyophilized 3G rPA anthrax vaccine candidate. At this point there can be no assurance that this product candidate will be shown to be safe and effective and approved by regulatory authorities for use in humans. Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at www.PharmAthene.com.

SOURCE PharmAthene, Inc.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
2. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
3. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
4. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
5. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
6. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
7. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
8. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
9. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
10. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
11. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , July 31, 2014 Hovione ... Ireland has successfully passed a pre-approval inspection by ... inspection, carried out by the FDA Consumer Safety Officer, Ms. ... started on 21 st July and concluded on the ... compliant with the principles and guidelines of Good Manufacturing Practices ...
(Date:7/31/2014)... 31, 2014 Catylix, Inc. ( ... Milpitas, California ) announced today the ... commercialize new fluorination products and related chemistry. ... from the use of substituents that are chemically ... polarity to improve binding and bioavailability. Fluorinated functional ...
(Date:7/31/2014)... , July 31, 2014 AFFiRiS AG ... York results of AFF008, a Phase I clinical ... the first therapy against the protein alpha-synuclein, a promising Parkinson,s ... J. Fox Foundation for Parkinson,s Research (MJFF) supported the study ... press conference on the impact a disease-modifying therapy would have ...
Breaking Medicine Technology:Successful FDA Inspection at Hovione's API Manufacturing Plant in Cork, Ireland 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4
... in a Single Pill to Target Three Major ... Next Phase of Development, ABBOTT PARK, Ill. and ... will advance the development of,Abbott,s next-generation fenofibrate ABT-335 and ... Phase III,clinical trials. The single pill would target all ...
... Aug. 30 ,Palatin Technologies, Inc. (Amex: PTN ... announced today that they have delayed plans for ... a first in class,melanocortin agonist drug candidate, for ... follows responses from representatives of,the U.S. Food and ...
Cached Medicine Technology:Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination 2Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination 3King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction 2
(Date:7/31/2014)... Leelanau Peninsula’s newest winery, Aurora Cellars ... 7788 East Horn Road in Lake Leelanau. Joining the Northern ... Cellars is the 25th winery along the trail. The winery ... tour events, making its trail event debut during the Harvest ... Owners David and Faye Mathia opened the boutique winery in ...
(Date:7/31/2014)... July 31, 2014 Ce-Classes.com has announced ... course for healthcare professionals, a Systematic Review of ... material published in the International Journal of Clinical and ... in response to a need to have accurate information ... the best treatment possible. The material provides a ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 In today’s world, ... difficult to get. Snoring and sleep apnea (a medical problem ... people and their bed partners of the rest they need ... of the population snores and 20 million people in the ... have been diagnosed and treated; and of those treated, many ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 The vineyards are ... the upcoming harvest. And, to celebrate, folks are gearing up ... Sunday, September 6 and 7, 2014 along the Leelanau ... an optional walk or run through the vineyards start-ing at ... Suttons Bay. A unique course between rows of grapevines offers ...
(Date:7/31/2014)... United Theological Seminary is pleased to welcome ... and Peter J. Bellini. Both began their teaching duties ... a Director of Non-Degree Programs, Mark Abbott, who begins ... Donne, Assistant Professor of New Testament, received a Ph.D. ... Second Temple Judaism, and Greek courses. His research interests ...
Breaking Medicine News(10 mins):Health News:Aurora Cellars Joins the Leelanau Peninsula Wine Trail 2Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leelanau Peninsula’s Annual Harvest Stompede Offers a Unique Vineyard Course for Walkers, Runners and Wine Tasters 2Health News:Growing Seminary Welcomes New Faculty 2
... type of disease, that requires insulin injections daily. Researchers ... this disease. Some medical research centers in the U.S. ... I diabetes by transplanting insulin-producing islet cells combined with ... live normal lives without insulin. , ...
... come up with a new technique of removing cancerous ... their hands and a special camera and instuments. This ... in significantly less time than the standard laproscopic procedure. ... of the American Urological Association by surgeons from the ...
... new gene which has the ability to slow down ... millions of people each year, and luckily tthe discovery ... the cancer of the colon, prostate,pancreas,brain and bowel. ... to stunt the cancer by starving the tumour ...
... from Mayo Clinic brings more choice in eating heath food// ... into any weight loss diets that restrict choices in food. ... the report that talks of sustainable eating habits that help ... weight requires a long-term commitment to making lifestyle changes. However, ...
... Researchers from UCLA had reported in the recent issue ... sleep suffer from loss of brain cells due to ... apnea, the person stops breathing during the sleep when ... in the brain as preB?tzinger complex (preB?tC), which is ...
... and its function has always left man dazzled for ... key factors// have been identified that could answer the ... babies and hence help treat prematurity. ,Identification ... brain damage repair in neurological diseases like multiple sclerosis ...
Cached Medicine News:Health News:Transplant helps diabetes 2Health News:Making operation and recovery time shorter 2Health News:New Healthy Weight Program Makes Healthy Eating More Interesting 2Health News:Sleep Apnea Related To Death And Loss Of Brain Cells 2Health News:Hyaluronic Acid – A Boon To The Problem Of Premature Infant 2
The adult blanket provides full coverage for patients of all sizes. The generous size and versatility of these blankets include extra material for the shoulders and feet. The foot drape also reduces ...
The cath lab blanket, designed for use in the Cardiac Cath Lab, surrounds the patient with warm air and allows unrestricted access to the femoral artery....
The Bair Hugger outpatient blanket makes it easy to give your patients the benefit of prewarming and enhance patient comfort during outpatient procedures....
The fabric is antistatic and non-linting and is both oil and water repellent.These superior blankets are an environmental friendly alternative to disposable blankets....
Medicine Products: